Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes and sells ...

Initial rounds of VC financing totaled $7.7 billion over 137 deals for biopharma in 2024, compared to $3.8 billion over 156 ...

The global biotechnology industry market size is projected to expand from USD 483.0 billion in 2024 to USD 546.0 billion by 2025, reflecting ...

Light Horse Therapeutics Inc., a developer of first-in-class small molecule therapeutics, today announced a $62 million Series A financing. The financing was led by founding investor Versant Ventures ...

The UK's self-regulated system for disclosing payments from drug companies to healthcare professionals and organizations is ...

Arjan van Manen joins BioLizard as Commercial Director, bringing over 20 years of commercial leadership experience in life sciences Meet BioLizard’s Arjan van Manen and CEO Liesbeth Ceelen at Biotech ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

This double-digit growth in new drug sales showcases the company's ability to successfully commercialize cutting-edge ...

The Biden administration’s justification of the first cycle of Medicare drug price negotiations is fueling curiosity and ...

RyCarma Therapeutics named Adam Rosenberg, former CEO of Aliada Therapeutics and Sionna Therapeutics, as its CEO. It also hired Jonathan Alspaugh as president and chief strategy officer and Sanjay ...

The stock's fall snapped a two-day winning streak.